Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen
2. Vanderbilt University Medical Center, Nashville, Tennessee;3. M. D. Anderson Cancer Center, Houston, Texas;4. University of Utah, Salt Lake City, Utah;5. Johns Hopkins University Hospital, Baltimore, Maryland